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Abstract
Bacteriophages have been shown to be effective for treating acute infections of the respiratory tract caused by antibiotic-resistant bacteria
in animal models, but no evidence has yet been presented of their activity against pathogens in complex biological samples from chronically
infected patients. We assessed the efficacy of a cocktail of ten bacteriophages infecting Pseudomonas aeruginosa following its addition to 58
sputum samples from cystic fibrosis (CF) patients collected at three different hospitals. Ten samples that did not contain P. aeruginosa were
not analysed further. In the remaining 48 samples, the addition of bacteriophages led to a significant decrease in the levels of P. aeruginosa
strains, as shown by comparison with controls, taking two variables (time and bacteriophages) into account (p = 0.024). In 45.8% of these
samples, this decrease was accompanied by an increase in the number of bacteriophages. We also tested each of the ten bacteriophages
individually against 20 colonies from each of these 48 samples and detected bacteriophage-susceptible bacteria in 64.6% of the samples. An
analysis of the clinical data revealed no correlation between patient age, sex, duration of P. aeruginosa colonization, antibiotic treatment,
FEV1 (forced expiratory volume in the first second) and the efficacy of bacteriophages. The demonstration that bacteriophages infect their
bacterial hosts in the sputum environment, regardless of the clinical characteristics of the patients, represents a major step towards the
development of bacteriophage therapy to treat chronic lung infections.
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Introduction
Despite improvements in patient management, infection
control policies, early detection and eradication therapies that
have increased the mean life expectancy of cystic fibrosis (CF)
patients to about 37 years, most of these patients eventually
succumb to chronic pulmonary bacterial infections [1–4]. The
most prominent pathogen in CF patients, the gram-negative
bacterium Pseudomonas aeruginosa, is becoming increasingly
resistant to antibiotics [5], leading to a gradual decrease in the
clinical benefits of antibiotic treatment over time.
In the environment, microbial communities are controlled
by various mechanisms, including the antagonistic action of
their specific viruses, through the combined activity of
temperate and virulent bacteriophages [6–10]. Bacteriophages
were used in medicine (phage therapy), back in the early 20th
century, before the discovery of the first antibiotics [11,12].
With the current alarming increase in the frequency of
infections caused by antibiotic-resistant pathogens and the lack
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of new antibiotics, phage therapy is returning to the spotlight.
There is recent support from experimental data and experi-
ence accumulated over 80 years in some European countries
(Georgia, Russia and Poland) for the use of virulent bacterio-
phages for treating lung infections [13–20]. As a further step
towards applications of bacteriophages in human medicine, we
evaluated their potential to infect bacteria in the challenging
environment of the lungs, by performing an ex vivo study on
sputum samples from 58 chronically infected CF patients.
Methods
Study design
We carried out a multicentre cross-sectional study on sputum
samples from 58 CF patients recruited from CF centres in
Montpellier (n = 23), Nancy (n = 20) and the Necker Hospital
in Paris (n = 15). This study was approved by the regional ethics
committee (Nıˆmes, registered under number 2011-A01197-34)
and declared to ClinicalTrial.gov (no. NCT01818206).
Bacteria and bacteriophage strains
We used the P. aeruginosa PAK strain to amplify bacterio-
phages PAK_P1, PAK_P2, PAK_P3, PAK_P4 and PAK_P5; the
CHA strain to amplify P3_CHA[20] and CHA_P1[19]; the
PAO1 strain for PhiKZ and LUZ19; and the Aa245 strain for
LBL3. Bacteriophages PhiKZ, LUZ19 and LBL3 were kindly
provided by R. Lavigne, KU Leuven, Belgium. The four
indicative strains (PAK, CHA, PAO1 and Aa245) were
cultured at 37°C in LB medium, with shaking, and bacterio-
phage lysates were prepared and purified as described
elsewhere [20]. The cocktail of these 10 bacteriophages was
freshly prepared from bacteriophage solutions, each of which
had been titrated on the corresponding host the day before
sample processing and on the day of processing. Bacteriophage
titration was performed by serial dilutions spotted in triplicate
on bacterial lawns. This cocktail was assembled from bacte-
riophages available in our laboratory without any prior
knowledge of their efficacy on a large collection of CF
P. aeruginosa strains.
New bacteriophages infecting colony #4 from sputum
sample 04 were isolated as described elsewhere [18].
Sputum sample processing
Four aliquots of sputum samples were used to evaluate the
count of bacteria and bacteriophages before and after
addition of the bacteriophage cocktail over 6 h (see Fig. 1
and Data S1). Bacteria were selected on cetrimide agar and
bacteriophage counts were obtained using the four indicative
strains.
FIG. 1. Schematic diagram of the
processing of sputum samples.
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The reproducibility and accuracy of our counting procedure
leading to the definition of threshold values are described in
detail in Data S1.
Test of the sensitivity of individual colonies to each
bacteriophage of the cocktail
We randomly selected 20 colonies (representative of the
proportions of mucoid/non-mucoid and small/large colonies)
from the cetrimide plates. The 15 lL of each colony grown in
broth were spotted on an LB plate, dried under a laminar flow
hood and subsequently a 0.5-lL drop of each bacteriophage
suspension (1 x 108 pfu/mL) was spotted on top of the dried
bacterial drops. Isolated plaques, confluent plaques or entirely
clear areas were considered to indicate that the bacteria were
susceptible to the phage tested, whereas the absence of
plaques indicated full resistance (Data S1).
Molecular genotyping of P. aeruginosa strains
Five colonies from sputum samples 03, 04 and 33 were chosen
for the molecular analysis (see Supplementary Excel file,
genotyping tab). The 16S RNA gene was amplified as previously
described [21], with a standard PCR kit (MP Biomedicals, Santa
Ana, CA, USA), from a single colony. The clonality of these 15
isolates was assessed by repetitive extragenic palindromic–
polymerase chain reaction (REP-PCR) adapted to a semi-auto-
mated format (DiversiLabTM system, bioMerieux, Marcy l’Etoile,
France) and fingerprinting profiles were analysed with
web-based DiversiLabTM software v.3.4 (bioMerieux).
Data analysis
The primary criterion assessed was the change in counts for
P. aeruginosa strains during the period of incubation in the
presence of bacteriophages. We calculated that, to detect a
50% decrease in bacterial counts with a standardized effect size
of 0.5, we would need to analyse n = 44 paired observations,
with an alpha risk of 0.05 and a beta risk of 0.10 (the
standardized effect size to estimate the number of subjects is
defined as the difference of the mean before and after divided
by the standard deviation). Thus, taking missing data into
account, we needed to enroll 55–60 consecutive patients in
this study. The secondary criteria taken into account were the
change in bacteriophage counts during the incubation period
and the susceptibility of the 20 individual colonies tested per
sample to each bacteriophage. Samples were then classified
into five groups, defined as: negative, for samples in which no
increase in bacteriophage counts was observed; group A, for
samples in which bacterial counts decreased and bacterio-
phage-susceptible bacteria were present; group B, for samples
displaying a decrease in bacterial counts and an absence of
susceptible colonies; group C, for samples displaying no
decrease in bacterial counts and the presence of susceptible
colonies; and group D for samples displaying no decrease in
bacterial counts and an absence of susceptible colonies (Fig. 3).
Statistical analysis
Descriptive data are summarized as means  standard devi-
ation (SD) or medians with interquartile ranges, according to
the normality of the distribution, which was assessed with the
Shapiro–Wilk test. We used Krukall–Wallis tests or ANOVA
tests for comparisons of quantitative variables. Categorical
data are expressed as numbers and percentages, and were
compared in chi-squared tests. Univariate and multivariate
analyses were carried out with linear mixed-effect models for
repeated measures. Variables were selected for inclusion in
the multivariate model if they had p-values below 0.20 in
univariate analysis, and a stepwise procedure was used to
select the final variables included in the multivariate model. A
p-value of ≤0.05 was considered statistically significant. Data
were analysed with R.2.15.2 software.
Results
Characteristics of the patients and treatment of the samples
The characteristics of the 58 CF patients enrolled in this study
are reported in Table 1. Each of the 58 sputum samples
collected was split into four aliquots. We added a cocktail of
ten bacteriophages infecting P. aeruginosa to one of these
aliquots and buffer alone to a second aliquot; the other two
aliquots were used for subsequent analysis (Fig. 1; Methods).
Bacterial counts were obtained on selective medium and
bacteriophage counts were obtained on agar plates overlaid
with four different indicative P. aeruginosa strains (Methods).
Ten sputum samples (20.8%) contained no P. aeruginosa strains
capable of growing on the selective medium and were not
TABLE 1. Principal characteristics of the CF patients
enrolled in this study
Variable Enrolled
Pseudomonas
aeruginosa-positivea
Patients 58b 48
Sex (female/male) 26/32 23/25
CFTR genotype n (%) n (%)
dF508/dF508 26 (45) 23 (48)
dF508/other 20 (34) 16 (33)
other/other 12 (21) 9 (19)
Age, yr (mean  SD) 26  10 27  10
Baseline FEV1
(% predicted, mean  SD)
52  20 52  19
aPseudomonas aeruginosa colonization was first recorded between years 1983 and
2011 (at least 3 months before inclusion), with the majority, 31 patients, between
years 1990 and 2000 and with only four patients in year 2011.
bTwenty-three patients from Montpellier, 15 from Paris (Necker Hospital) and 20
from Nancy.
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analysed further (see Supplementary Excel file, bacteria
numeration tab).
Analysis of the microbiological data (bacteria and
bacteriophages)
In CF patients, P. aeruginosa populations displayed several
phenotypes that could affect susceptibility to bacteriophages
[22,23]. We then expected bacteria to grow when samples
were incubated in the absence of bacteriophages, while
significant growth attenuation was predicted in the presence
of bacteriophages. A statistical analysis was performed on the
48 samples, in which bacterial counts (ranging from 33% to
6090% increase in the absence and from 18 to 98% reduction
in the presence of bacteriophages) were compared in a mixed
linear model with two parameters: time (0 h and 6 h) and
bacteriophages (presence vs. absence). This analysis confirmed
that the total number of bacteria increased during the
incubation period in the absence of bacteriophages
(p < 0.001). However, despite this growth, the addition of
bacteriophages significantly decreased the number of bacteria
present (p 0.024).
The secondary criterion considered was the difference
between the number of bacteriophages added and the number
recovered at the end of the incubation period. As bacterio-
phage counts can only increase if the bacteriophages infect
bacterial hosts, any increase over the threshold level indicates
that some of the bacteria in the sample were infected (Fig. 2,
Methods; see Supplementary Excel file, threshold evaluation
and phage numeration tabs). The results obtained for the four
indicative strains were combined, and only seven samples
(14.6%) (Fig. 3; see Supplementary Excel file, analyses tab)
displayed no increase in the number of bacteriophages over
the threshold level (these seven samples were assigned to the
negative group). The other 41 samples displayed an increase in
bacteriophage numbers. We analysed these 41 samples by
considering two additional criteria: (i) the decrease in bacterial
counts and (ii) the susceptibility of 20 individual colonies to at
least one of the ten bacteriophages (Methods; see Supplemen-
tary Excel file, susceptibility to phages tab). This led to the
definition of four groups (Fig. 3, Methods): group A, which
included 17 samples (35.4%), group B, which contained five
samples (10.4%), group C, which contained nine samples
(18.8%) and group D, which contained ten samples (20.8%)
(see Methods and Supplementary Excel file, analyses tab
including the results obtained for each indicative strain).
We used a dichotomous scoring system, no lysis vs. lysis
(Methods), to analyse the susceptibility of 20 individual
colonies from each sputum sample to each of ten bacterio-
phages (over 8900 tests). Bacteriophages PAK_P5, LBL3,
PAK_P3 and PAK_P4 were the most efficient, infecting 170,
156, 151 and 149 colonies, respectively, whereas bacterio-
phages CHA_P1 and PhiKZ were the least efficient, infecting
only 23 and 32 colonies, respectively, of a total of 892
(Table 2; see Supplementary Excel file, susceptibility to phage
tab). The ten bacteriophages were able to infect up to 313
individual colonies, corresponding to a coverage of 35.1%, a
low value, which could reflect the lack of initial selection for
ability to infect P. aeruginosa strains from CF patients.
We also carried out a molecular analysis of five colonies
isolated from each of three samples, one from group A, one
from group B and one from group D. 16S RNA sequences
confirmed that these 15 colonies belonged to P. aeruginosa.
Genotyping confirmed that each set of five colonies belonged
to the same group, suggesting that each of the corresponding
patients was infected by one major genotype (Fig. 4). For the
five colonies selected from the group D sample, all of which
were resistant to all ten bacteriophages, we selected a single
colony for the isolation of new bacteriophages from environ-
mental sources. Three of these new bacteriophages, chosen at
random, infected all five colonies from the group D sample,
demonstrating that these colonies were not resistant to
bacteriophage infection per se.
The presence of bacteriophages in the sputum samples
before processing was assessed by checking for plaques
following spotting of the sample on the four indicative strains
(see Supplementary Excel file, prophages tab). Only a few
plaques were observed from 11 samples, corresponding to no
more than 2 x 103 pfu/mL in each sample. Prophages were
also detected during the testing of individual colonies for
susceptibility to bacteriophages, in the form of tiny homoge-
FIG. 2. Increase of bacteriophage counts following 6 h incubation.
Individual data (% of increase between 0 and 6 h) are indicated for the
41 samples that have an increased value above the threshold from spot
tests performed on each of the four indicative strains (PAK, PAO1,
CHA and Aa245). The lines represent median values.
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neous plaques covering the entire surface of the indicative
strain spot. In total, 29 colonies from eight sputum samples
presented such a phenotype (see Supplementary Excel file,
prophages tab). The presence of these bacteriophages and
prophages at such a low level did not prevent the determi-
nation of bacteriophage counts and colony sensitivity.
Correlation between patient characteristics and
microbiological data
We investigated the correlation between group (negative, A, B,
C or D) and clinical data (see Supplementary Excel file, clinical
data tab), by performing a statistical analysis with several
parameters (age, sex, FEV1, last antibiotic treatment and
duration of colonization; Table 3). We found no link between
these five groups, defined on the basis of microbiological data,
and the clinical parameters tested (all p-values above 0.05).
Discussion
In the face of the growing threat posed by antibiotic-resistant
strains and the particular microenvironment of the lungs of CF
patients, the development of effective treatments is a major
challenge. Mucus, pathogens (bacteria, fungi and viruses),
FIG. 3. Diagram of the analysis of microbiological data. The 48 samples containing P. aeruginosa strains were classified into five groups according to
counts of bacteriophages, counts of bacteria and susceptibility to individual colonies. *, including bacteria increase; **, including bacteriophages
decrease. Amongst the seven samples of the negative group, one displayed an increase in bacteria counts, two a decrease and four a non-significant
variation. Four samples out seven contained at least one colony susceptible to bacteriophages.
TABLE 2. Susceptibility of CF isolates to individual bacte-
riophages
Number of CF isolates Resistant Sensitive Total
PAK-P1 813 79 892
PAK-P2 796 96 892
PAK-P3 741 151 892
PAK-P4 743 149 892
PAK-P5 722 170 892
P3-CHA 767 125 892
CHA-P1 869 23 892
PhiKZ 860 32 892
Luz19 797 95 892
LBL3 736 156 892
Total for the cocktail 7844 1076 8920
FIG. 4. Molecular typing of 15
P. aeruginosa colonies isolated from three
sputum samples. Dendrogram, REP-PCR
patterns and similarity matrix
(colour-coded, based on percentage
similarity) are represented for five
randomly chosen colonies from samples
03, 04 and 33.
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extracellular materials (chemokines, DNA, proteases, etc.) and
inflammatory cells form a barrier potentially preventing or
interfering with antibacterial treatments. The renewed interest
in phage therapy and its successful use against acute P. aeru-
ginosa lung infections in mice led us to investigate whether
bacteriophages could effectively infect bacteria in the sputum
of CF patients. Using a set of 58 sputum samples collected
from three hospitals in France, we demonstrated the efficacy
of a cocktail of ten bacteriophages not specifically selected for
their ability to infect P. aeruginosa strains in sputum. Thus, the
microenvironment in the lungs of CF patients does not
prevent bacteriophage activity as we found that the number of
bacteriophages increased over the threshold value in 86.4%
(41 out 48 samples containing P. aeruginosa strains) of samples.
Furthermore, none of the clinical parameters tested was
associated, either positively or negatively, with bacteriophage
efficacy. This patient-independent efficacy supports the further
development of bacteriophage treatments.
However, this pioneering study had some limitations. First,
only bacteria growing on the selective medium within 24 h
were taken into account, but some P. aeruginosa strains
require longer incubation times for colony formation. This
may account for the increase in bacteriophage counts in seven
of the ten samples classified as not containing P. aeruginosa
strains. Second, we used a short incubation period, to optimize
the detection of decreases in bacterial counts by bacterio-
phages, because we expected the sputum samples to contain a
mixed population of bacteriophage-susceptible and bacterio-
phage-resistant colonies.
Group A samples gave the most straightforward results,
whereas the results for group B can be explained by a shift in
phenotype to bacteriophage susceptibility between the sputum
and agar plate environments. Upon environmental signals it is
known that bacterial gene expression can affect bacteriophage
susceptibility [24,24]. In group C samples, the decrease in the
bacteriophage-susceptible population was probably compen-
sated for by an increase in the bacteriophage-resistant
population. Group D samples probably contained a minor
bacteriophage-susceptible population and a larger bacterio-
phage-resistant population. Finally, some negative group sam-
ples were found to contain isolated colonies susceptible to
bacteriophages, suggesting that bacteria may be less suscep-
tible to bacteriophage infection in the sample than on plates.
Furthermore, patient factors (immune cells, proteases, etc.)
and other microorganisms (fungi and viruses) may also hinder
interactions between bacteriophages and bacteria.
In sputum samples, the amplification of individual bacterio-
phages could be evaluated only for LBL3 (infecting only one
indicative strain), which gave the two highest levels of bacterio-
phage amplification (samples 50 and 58). LBL3 was also the
second most active bacteriophage in analyses on isolated
colonies (see Supplementary Excel file, phages numeration
tab). The most active bacteriophage, PAK_P5, is genetically
closely related to PAK_P3, P3_CHA and CHA_P1 (the least
active of the ten bacteriophages tested). These four bacterio-
phages had protein sequences that were about 90% identical.
The genomic data of bacteriophages is therefore insufficient for
predicting infectivity in clinical bacterial strains [19].
TABLE 3. Correlation between clinical and microbiological data for 48 patients
Variable
Negative group
(n = 7) Group A (n = 17) Group B (n = 5) Group C (n = 9) Group D (n = 10) p-valuea p-valueb
Sex
F 2 (28.57) 8 (47.06) 2 (40.00) 7 (77.78) 4 (40.00) 0.3571 0.3332
M 5 (71.43) 9 (52.9) 3 (60.00) 2 (22.22) 6 (60.00)
Age 37.43  18.24 24.53  9.08 27.40  6.35 28.78  7.15 21.90  3.81 0.0854 0.1891
FEV1 (%) 50.57  13.88 54.00  20.86 54.60  25.02 44.78  17.07 52.50  20.39 0.9377 0.8334
Antibiotic
A 0 (0.00) 2 (6.90) 1 (11.11) 0 (0.00) 2 (12.50) 0.5557 0.5220
Am 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.25)
Az 1 (14.29) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
B 0 (0.00) 2 (6.90) 0 (0.00) 0 (0.00) 1 (6.25)
C 1 (14.29) 3 (10.34) 2 (22.22) 5 (33.33) 1 (6.25)
Cl 0 (0.00) 1 (3.45) 0 (0.00) 0 (0.00) 0 (0.00)
Co 0 (0.00) 1 (3.45) 1 (11.11) 1 (6.67) 1 (6.25)
F 1 (14.29) 4 (13.79) 1 (11.11) 1 (6.67) 1 (6.25)
M 1 (14.29) 5 (17.24) 0 (0.00) 3 (20.00) 3 (18.75)
N 4 (57.14) 9 (31.03) 2 (22.22) 3 (20.00) 2 (12.50)
P 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (12.50)
R 0 (0.00) 1 (3.45) 0 (0.00) 0 (0.00) 0 (0.00)
T 1 (14.29) 0 (0.00) 1 (11.11) 2 (13.33) 0 (0.00)
Tg 1 (14.29) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
To 2 (28.57) 1 (3.45) 1 (11.11) 0 (0.00) 2 (12.50)
Length of colonization
z(months)
160.71  48.21 170.52  86.44 157.00  92.36 122.33  95.29 127.20  73.66 0.6413 0.5182
Last antibiotic administered to patients (A, amoxicillin + clavulanic acid; Am, amikacin; Az, aztreonam; B, cotrimoxazole; C, ciprofloxacin; Cl, ticarcillin + clavulanic acid; Co,
colimycin; F, ceftazidime; M, meropenem; N, tobramycin/intravenous; P, pristinamycin; R, rifampicin; T, piperacillin + tazobactam; Tg, teicoplanin; To, tobramycin/aerosol).
ap-value for the five groups.
bp-value for the four groups (A,B,C,D). Statistical analyses were performed using the chi-square test for categorical variables and ANOVA or Kruskal–Wallis tests for quantitative
variables.
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CF patients colonized by a single clonal population of
P. aeruginosa displayed several phenotypes [22,23]. Conse-
quently, it was not surprising to observe that the 20 colonies
isolated from a single sputum sample were not equally infected
by the ten individual bacteriophages, in any of the 48 samples
(except those containing only resistant colonies). This con-
firms that various phenotypes can emerge from a unique
genotype in the sputum of a patient, which can indeed affect
bacterial susceptibility to bacteriophages. It is also an indication
that genotyping may be to imprecise for the identification of
clonal mutations relevant to bacteriophage susceptibility.
Testing a set of bacteriophages against a large panel of isolated
colonies for each patient would therefore be the best
approach for formulating bacteriophage cocktails. However,
the possibility of phenotypic variation between the sputum and
agar plate environments represents an additional drawback.
Nevertheless, our recent results clearly suggest that the most
efficient bacteriophages in vivo are likely to be those isolated
‘deliberately’, using patients’ strains, supporting the use of a
personalized approach to achieve optimal treatment
[19,26,27].
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